| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A controlled trial of a human papillomavirus type 16 vaccine.
|
N Engl J Med
|
2002
|
10.58
|
|
2
|
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
|
Lancet Oncol
|
2005
|
9.67
|
|
3
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
|
J Infect Dis
|
2009
|
5.09
|
|
4
|
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
|
Obstet Gynecol
|
2006
|
4.33
|
|
5
|
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
|
J Natl Cancer Inst
|
2010
|
4.20
|
|
6
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
|
J Infect Dis
|
2009
|
3.55
|
|
7
|
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
|
BMJ
|
2010
|
3.41
|
|
8
|
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
|
Vaccine
|
2006
|
2.78
|
|
9
|
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
|
BMJ
|
2012
|
2.77
|
|
10
|
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
|
Cancer Prev Res (Phila)
|
2009
|
2.42
|
|
11
|
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
|
Obstet Gynecol
|
2009
|
2.13
|
|
12
|
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
|
Vaccine
|
2008
|
2.09
|
|
13
|
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.
|
Sex Transm Infect
|
2011
|
1.78
|
|
14
|
Safety of influenza vaccination during pregnancy.
|
Am J Obstet Gynecol
|
2009
|
1.77
|
|
15
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
|
J Low Genit Tract Dis
|
2015
|
1.73
|
|
16
|
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
|
Hum Vaccin
|
2009
|
1.66
|
|
17
|
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
|
Vaccine
|
2007
|
1.53
|
|
18
|
Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection.
|
Infect Dis Obstet Gynecol
|
2003
|
1.44
|
|
19
|
Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists.
|
Infect Dis Obstet Gynecol
|
2005
|
1.37
|
|
20
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
|
Obstet Gynecol
|
2015
|
1.30
|
|
21
|
Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors.
|
Perspect Sex Reprod Health
|
2005
|
1.11
|
|
22
|
Beyond likes and tweets: an in-depth look at the physician social media landscape.
|
Clin Obstet Gynecol
|
2013
|
1.06
|
|
23
|
Surfactant proteins A and D enhance the phagocytosis of Chlamydia into THP-1 cells.
|
Am J Physiol Lung Cell Mol Physiol
|
2004
|
0.92
|
|
24
|
Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments.
|
Vaccine
|
2013
|
0.86
|
|
25
|
Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection.
|
Mol Hum Reprod
|
2004
|
0.83
|
|
26
|
A role for surfactant protein D in innate immunity of the human prostate.
|
Prostate
|
2005
|
0.82
|
|
27
|
Cervical cancer prevention: better tests, better tools, and more equitable outcomes.
|
J Natl Cancer Inst
|
2011
|
0.81
|
|
28
|
Does rubella immunity predict measles immunity? A serosurvey of pregnant women.
|
Infect Dis Obstet Gynecol
|
2006
|
0.81
|
|
29
|
Regulation of surfactant protein D in the mouse female reproductive tract in vivo.
|
Mol Hum Reprod
|
2007
|
0.79
|
|
30
|
Advancing human papillomavirus research with a rhesus monkey model.
|
J Natl Cancer Inst
|
2011
|
0.75
|
|
31
|
Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.
|
Cancer Epidemiol
|
2012
|
0.75
|
|
32
|
Women's health providers as vaccine providers in public health emergencies.
|
J Reprod Med
|
2014
|
0.75
|
|
33
|
Cervical Cancer Screening in the United States-Affiliated Pacific Islands: Options and Opportunities.
|
J Low Genit Tract Dis
|
2016
|
0.75
|